News

Chugai gains Japanese approval for Perjeta and Bonviva

28-06-2013

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said this morning (June 28) that it has obtained…

Anti-Arthritics/RheumaticsAsia-PacificBonvivaChugai PharmaceuticalOncologyPerjetaPharmaceuticalRegulationRoche

Eli Lilly and Chugai to stop co-marketing of Evista in Japan

05-11-2012

The Japanese subsidiary of US drug major Eli Lilly (NYSE: LLY) and Roche's (ROG: SIX) majority-owned…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalEli LillyEvistaLicensingMarkets & MarketingPharmaceutical

Uptake of alternative biologics such as Roche/Chugai's Actemra/RoActemra will erode RA market share of TNF-alpha inhibitors through 2019

30-07-2010

In the rheumatoid arthritis (RA) drug market, the uptake of alternative biologics such as Roche/Chugai's…

ActemraAnti-Arthritics/RheumaticsAstraZenecaBiotechnologyChugai PharmaceuticalMarkets & MarketingPfizerPharmaceuticalRoActemraRoche

Back to top